INS and COVID-19: Our results indicate a higher relative risk of COVID‐19 mortality and hospitalization associated with the prescription of insulin—possible related to an increased inflammatory milieu in patients with type 2 diabetes and COVID‐19 on insulin—and a lower risk of these outcomes in people prescribed MF, with no statistical difference in the magnitude of the associations across ethnic groups.4